Better Buy: CRISPR Therapeutics vs. Intellia
There's no shortage of promising gene-editing stocks on the market for investors to choose from. Both CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA) have caught plenty of attention for their promising drug candidates, many of which have the potential to become major blockbusters.
However, the two companies also have differences that investors should keep in mind. Let's go over what sets these two biotech stocks apart, where they overlap, and which is a better investment at this time.
Image source: Getty Images.
Source Fool.com
